RBN-2397, which exploits PARP7′s role in regulating the IFN-I signaling, is currently in a Phase 1 clinical trial designed to assess its anti-tumor activity in patients with advanced-stage solid tumors (NCT04053673). The gene discussed is TIPARP; the disease is neoplasm.